Final Answer:
The accurate statement is Pyridoxine (B6) is contraindicated during isoniazid therapy as it may exacerbate neuritis. Therefore, option number 3 is correct.
Step-by-step explanation:
Isoniazid (INH) is known to deplete vitamin B6 (pyridoxine), leading to a risk of peripheral neuropathy. To counteract this side effect, it is recommended to administer pyridoxine supplements during isoniazid therapy. Therefore, the statement that pyridoxine (B6) is contraindicated during isoniazid therapy is inaccurate. Instead, pyridoxine supplementation is a crucial component to prevent and mitigate potential neurotoxic effects.
Additionally, the other statements are not accurate in the context of isoniazid administration. Isoniazid is preferably given on an empty stomach, as food may decrease its absorption. Administering isoniazid concurrently with phenytoin (Dilantin) is not safe, as both drugs may compete for the same metabolic pathway, potentially leading to suboptimal therapeutic effects or toxicity. Monitoring for the resolution of symptoms is necessary during isoniazid treatment to assess the effectiveness of the therapy and to detect any adverse reactions promptly.
Understanding the appropriate administration and considerations for isoniazid is crucial for the successful treatment of tuberculosis and the prevention of potential side effects. This knowledge ensures that healthcare professionals can optimize therapeutic outcomes and provide safe and effective care for patients undergoing isoniazid therapy.